↓ Skip to main content

American Association for Cancer Research

Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia HiDAC + Pembrolizumab in R/R AML

Overview of attention for article published in Blood Cancer Discovery, September 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#41 of 204)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
5 news outlets
twitter
19 X users

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
31 Mendeley
Title
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia HiDAC + Pembrolizumab in R/R AML
Published in
Blood Cancer Discovery, September 2021
DOI 10.1158/2643-3230.bcd-21-0070
Pubmed ID
Authors

Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic Moore, Karen P. McKinnon, Alec D. Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan A. Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo

X Demographics

X Demographics

The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 13%
Other 3 10%
Researcher 3 10%
Student > Bachelor 3 10%
Student > Master 2 6%
Other 2 6%
Unknown 14 45%
Readers by discipline Count As %
Medicine and Dentistry 5 16%
Biochemistry, Genetics and Molecular Biology 4 13%
Agricultural and Biological Sciences 2 6%
Unspecified 1 3%
Immunology and Microbiology 1 3%
Other 3 10%
Unknown 15 48%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2023.
All research outputs
#900,274
of 25,163,238 outputs
Outputs from Blood Cancer Discovery
#41
of 204 outputs
Outputs of similar age
#20,904
of 423,746 outputs
Outputs of similar age from Blood Cancer Discovery
#2
of 16 outputs
Altmetric has tracked 25,163,238 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 204 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.6. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,746 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.